Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of TAK503 versus atomoxetine in children and adolescents with ADHD (Phase 4, 2-part study)
2018-000821-29Phase 4Active
- Sponsor
- Takeda
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of TAK-503 in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Takeda. Primary endpoint: Change from baseline in CANTAB RTI task. Started May 2019; status: active.
02
Drugs
TAK-503
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2018-000821-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000821-29.